Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.00
Bid: 44.00
Ask: 46.00
Change: 0.00 (0.00%)
Spread: 2.00 (4.545%)
Open: 45.00
High: 45.00
Low: 45.00
Prev. Close: 45.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Synthomer predicts revenue decline amid challenges

Tue, 30th Jan 2024 12:27

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Berkeley Energia Ltd - Spain-focused clean energy company, focused on bringing the Salamanca project in Western Spain to production - Spot uranium prices jump 27% in the quarter to December 31, ending at USD91 per pound, and further rise to about USD100 per pound in January. "The outlook for nuclear power and the uranium market continued to strengthen during the quarter," Berkeley Energia says. Meanwhile, disagrees with decision by High Court of Justice of Castilla y Leon in Spain. The court upheld appeals to revoke judgements for authorisation of exceptional use of the land and the urbanism licence. Berkeley Energia plans to appeal the judgement at Spain's Supreme Court under Spanish law "to defend its position and take all necessary actions to preserve its rights."

----------

Cambridge Cognition Holdings PLC - Cambridgeshire, England-based company which develops and markets digital solutions to assess brain health - Swings to adjusted operating profit of GBP900,000 in 2023 from a loss of GBP2.1 million in 2022. Revenue grows 7.1% to GBP13.5 million in 2023 from GBP12.6 million. Looking ahead, company says: "There has been considerable merger & acquisition activity by large pharmaceutical companies in the central nervous system drug development sector recently and, together with an improving global economic outlook, that is expected to prompt further investment in CNS clinical trials." Chief Executive Officer Matthew Stork adds: "Despite challenging market conditions during 2023, the company has strengthened its technology platforms and commercial offering and is positioned to capitalise on the anticipated growth in the CNS drug development market. We continue to focus on delivering profitable growth and driving success over the medium-term." Cambridge Cognition will release its 2023 results in April.

----------

Diversified Energy Co PLC - owner of US oil and gas wells - Average net daily production edges up 1.3% to 136,800 barrels of oil equivalent in 2023, from 135,000 in 2022. Estimated adjusted earnings before interest, tax, depreciation and amortisation are set to rise at least 7.4% to between USD540 million and USD545 million in 2023, from USD503 million in 2022. CEO Rusty Hutson says: "Despite a challenging commodity price environment, we generated strong full year results, including growing Ebitda to a record level that exceeded consensus expectations," adding: "Diversified continues to grow as a solutions-based business, making it the right company at the right time."

----------

Flowtech Fluidpower PLC - Wilmslow, England-based supplier of technical fluid power products - Revenue in Great Britain declines 6.2% to GBP79.3 million in 2023, from GBP84.5 million in 2022. In Ireland, revenue climbs 13% to GBP22.0 million from GBP19.5 million. In the Benelux countries, revenue edges up 0.5% to GBP10.8 million. The company says that underlying profit for 2023 is anticipated to be in line with market expectations. Cites market expectations of underlying earnings before interest and tax of GBP6.0 million and underlying pretax profit of GBP4.6 million. Chair Roger McDowell says: "In 2023, we welcomed Mike England as our new CEO. With some significant team changes, he has focussed on implementing the near term performance improvement plan and the refreshed strategy to enable the firm platform from which the business can grow over the medium term. Whilst 2023 has been a more difficult year, I am confident that the actions Mike and his team are taking will drive strong returns in shareholder value."

----------

Harworth Group PLC - focused on the regeneration of land and property for sustainable development and investment - Expects EPRA net disposal value as at December 31 to be slightly ahead of current market consensus of 194.0 pence, which has a range of 189.5p to 195.6p. For December 31, 2022, the company had reported an EPRA NDV of 196.5p. The company says that its anticipated EPRA NDV "is the result of management actions undertaken on development sites to unlock high value uses, and positive progress with planning applications, which have underpinned valuation gains". Chief Executive Officer Lynda Shillaw says: "As we enter 2024, there are some signs of optimism in the macro environment whilst our key markets remain characterised by structural undersupply. We are encouraged that we are seeing continued good demand into the new year for our serviced residential land as well as occupier interest in our employment sites."

----------

Synthomer PLC - Essex, England-based chemicals manufacturer - Anticipates revenue decline of 16% to GBP2.0 billion in 2023 from GBP2.38 billion in 2022. Adjusted Ebitda will be between GBP140 million and GBP144 million in 2023. For 2022, Synthomer had reported Ebitda of GBP249.2 million. Year-end net debt is expected to decrease 51% to GBP499 million, ahead of its own expectations, from GBP1.02 billion a year prior. Synthomer cites "strong cash delivery in the final quarter" for the net debt reduction. The company says trading in the fourth quarter was consistent with trends throughout the year, with subdued volumes and limited visibility amid ongoing challenging macroeconomic conditions in the chemicals industry. Looking ahead, CEO Michael Willome says: "In the near term, our focus remains on enhancing our strong positions in key speciality end-markets, optimising our business portfolio and cost position, and sustaining our demonstrated ability to generate free cash flow despite the challenging demand environment."

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
20 Sep 2018 12:35

Cambridge Cognition Holdings Loss Widens As Revenue Drops

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Thursday that its loss for the first half of the financial year widened as it recorded a drop in revenue as a result of the new IFRS

Read more
19 Sep 2018 12:45

Cambridge Cognition To Provide NeuroVocalix For Virtual Clinical Tests

LONDON (Alliance News) - Cambridge Cognition Holdings PLC on Wednesday said it signed its first commercial contract with an undisclosed pharmaceutical firm for its recently launched NeuroVocalix a

Read more
19 Sep 2018 10:14

Cambridge Cognition announces first NeuroVocalix commercial partnership

(Sharecast News) - Neuroscience technology company Cambridge Cognition Holdings announced its first commercial partnership for its recently launched 'NeuroVocalix' voice biomarker technology on Wednesday.

Read more
13 Sep 2018 11:14

Cambridge Cognition's NeuroVocalix Set For Clinical Trial Use

LONDON (Alliance News) - Neuroscience technology firm Cambridge Cognition Holdings PLC on Thursday said its NeuroVocalix platform is ready for clinical trials.NeuroVocalix, the company to a

Read more
1 Aug 2018 11:51

Cambridge Cognition Inks US Production Distribution For CANTAB

LONDON (Alliance News) - Cambridge Cognition Holdings PLC said Wednesday that it signed a commercial collaboration with health provider Healthy Amplified to launch its software product to better a

Read more
17 May 2018 16:01

UK Shareholder Meetings Calendar - Next 7 Days

Friday 18 MayPaddy Power BetfairIndependent News & (T)PetrofacJohn Group (re by

Read more
22 Mar 2018 13:03

Cambridge Cognition Shares Fall As It Swings To Annual Loss

LONDON (Alliance News) - Shares fell in Cambridge Cognition Holdings PLC on Thursday as it swung to a loss in 2017 from a maiden profit due to higher costs and lower in the at

Read more
14 Mar 2018 12:47

Oil majors give in to investors with share buyback spree

By Nivedita Bhattacharjee March 14 (Reuters) - After almost three barren years for investors who have poured millions into the U.S. oil sector, producers are finally to

Read more
25 Jan 2017 08:27

Cambridge Cognition gains US regulatory approval for memory test

(ShareCast News) - Neuroscience digital health company Cambridge Cognition has gained regulatory clearance for its memory test to be used as a medical device in the US. Cantab Mobile, which detects clinically-relevant memory impairment in older adults at the point of care, received 510k clearance fo

Read more
13 Oct 2016 10:55

Cambridge Cognition confirms series of new contracts

(ShareCast News) - Neuroscience company Cambridge Cognition Holdings announced a series of new contracts worth more than £0.25m on Thursday, to assess - through CANTAB Connect - the abuse potential of investigational drugs in a new market application for the company. The AIM-traded firm claimed that

Read more
22 Sep 2016 10:23

Cambridge Cognition's sales up after investments in marketing

(ShareCast News) - Cambridge Cognition' half-year revenues grew and losses were more than halved as the neuroscience software and hardware company's invested in marketing and development. For the six months ended 30 June, revenue increased by 11.3% to £3.26, compared to the same period last year. T

Read more
22 Sep 2016 08:51

Cambridge Cognition Loss Narrows On Strong Revenue Growth

Read more
20 Sep 2016 08:07

Cambridge Cognition Inks First Contract For CANTAB Recruit Product

Read more
16 Aug 2016 13:49

Cambridge Cognition announces promising results from technology study

(ShareCast News) - Neuroscience company Cambridge Cognition Holdings announced results on Tuesday from a new technology feasibility study. The AIM-traded firm, which develops and markets near-patient technologies for the assessment of brain health to improve the drug development process, said the re

Read more
20 Jul 2016 07:49

Cambridge Cognition Signs GBP500,000 CANTAB Deal With Biobank

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.